ClinicalTrials.gg
RecruitingNCT02132741Updated May 13, 2026

Optical Coherence Tomography And NEphropathy: The OCTANE Study

An observational study in Health, Hypertension and Chronic Kidney Disease, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by University of Edinburgh · Observational

From the registry’s dates

  • Started May 2014; still recruiting 12 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients with high blood pressure (hypertension) and chronic kidney disease are at an increased risk of developing heart disease and strokes. Part of this risk is due to changes in the structure and function of the blood vessels throughout the body. It is thought that reducing high blood pressure and treating chronic kidney disease improves the structure and function of blood vessels but information on this is limited. Optical coherence tomography (OCT) is a method of looking at the blood vessels at the back of the eye. It is a simple, quick and non-invasive test that you may have previously had during a visit to the optician. The purpose of the study is to ascertain whether OCT is able to detect changes in the eye's blood vessels in patients with hypertension and chronic kidney disease compared to healthy individuals and also to see if any differences seen improve with treatment.

Read the detailed description

This project is an exploratory study, using enhanced depth imaging with the new SPECTRALIS OCT, designed to examine choroidal and microvascular retinal structure in patients with hypertension, chronic kidney disease (CKD), and in age and sex matched healthy controls. The study is non-invasive and takes only a few seconds to acquire these complex images. The Centre, where the images will be captured and where image analysis systems are located, is on the Royal Infirmary of Edinburgh (RIE) site close to the RIE outpatient clinics, making recruitment easy.

02

Conditions studied

  • Health
  • Hypertension
  • Chronic Kidney Disease

Keywords

  • OCT; hypertension; CKD
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 150 is below the median of 350 across 1,163 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healthy volunteers will be recruited from a research database. CKD and patients with hypertension will be recruited from these respective clinics in secondary care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age 18-80
  • ≤35
  • For those with hypertension: BP ≥140/90 or on treatment for hypertension
  • For those with CKD: CKD as defined by the Kidney Diseases Quality Initiative guidelines

Exclusion criteria

Exclusion Criteria:

  • Subject is below the age of legal consent, or is mentally or legally incapacitated
  • The subject has donated blood (450 ml) within the last 4 weeks
  • Past or present drug or alcohol abuse including intravenous drug abuse at any time
  • Participation in another clinical trial within 1 month
  • Considered to be at high risk of or
  • Patients with known eye disease, or previous eye surgery, or refractive error greater than +/- 6 dioptres.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Treated hypertension

    Patients on treatment for hypertension

  • CKD-ESRD

    Pre- \& post haemodialysis

  • Healthy individuals

    Healthy volunteers

  • Chronic kidney disease

    Pre-dialysis CKD \& those with a functional renal transplant

  • Hypertension

    Untreated

06

What researchers measure

Primary outcomes

  1. Choroidal & retinal morphology

    A composite measures outcome including: 1. Sub-foveal choroidal thickness 2. Choroidal volume 3. Retinal vasculature morphology and optimality measurements (arteriolar thickness, branching coefficient and branching angle; fractal dimension, and venular tortuosity.)

    Time frame: 2 weeks

Secondary outcomes

  1. Neuro-retinal metrics

    A composite measures outcome of neuro-retinal metrics (retinal thickness, retinal nerve fibre layer thickness)

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
  • University of Edinburgh
    Edinburgh, Midlothian EH164TJ, United Kingdom
    Recruiting
    • Neeraj Dhaun, MD PhD · Principal investigator
08

References and documents

Publications

  • Balmforth C, van Bragt JJ, Ruijs T, Cameron JR, Kimmitt R, Moorhouse R, Czopek A, Hu MK, Gallacher PJ, Dear JW, Borooah S, MacIntyre IM, Pearson TM, Willox L, Talwar D, Tafflet M, Roubeix C, Sennlaub F, Chandran S, Dhillon B, Webb DJ, Dhaun N. Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. JCI Insight. 2016 Dec 8;1(20):e89173. doi: 10.1172/jci.insight.89173. PubMed 27942587 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2014 (actual). Primary completion is estimated for Dec 2027, 163 months after the start.

Of 345 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 163 months is above that.

Counting every sponsor, half of 426 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2014
First posted
May 7, 2014
StartActual
May 16, 2014
Primary completionEst.
Dec 31, 2027
CompletionEst.
Sep 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02132741
Responsible party
Sponsor
First posted
May 7, 2014
Start date
May 16, 2014
Primary completion
Dec 31, 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
May 13, 2026

Study contacts

Neeraj Dhaun, MD PhD
Contact
bean.dhaun@ed.ac.uk
01312429215
David Webb
Contact
d.j.webb@ed.ac.uk
01312429215
Neeraj Dhaun, MD PhD
principal investigator · University of Edinburgh

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion